The Sareum Holdings Plc (LON: SAR) share price rose by 4.76% after revealing the results of its phase I/II clinical trial of its SRA737 clinical-stage oral, selective small molecule Checkpoint kinase 1 (Chk1) inhibitor combined with the popular chemotherapy drug gemcitabine.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
The trial results were published in the November 15 edition of Clinical Cancer Research, creating renewed interest in the company and its SRA737 molecule. The last time we heard about the molecule was when Sierra Oncology decided to return the rights to the molecule to Sareum and its partner, the CRT Pioneer Fund LP (CPF).
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Investors muted reaction to the news could have been driven by the fact that the trial data was first released at the American Society of Clinical Oncology (ASCO) meeting in 2019. Therefore, this was old clinical trial data that it being released at an opportune moment.
Sareum and the CRT Pioneer Fund LP are currently weighing their options regarding the best course of action for the promising Chk1 molecule. In addition, the data released is unique since this was the first time the molecule had been paired with a popular chemotherapy treatment, gemcitabine.
The clinical trial’s primary objective was to establish a safety profile, recommend the Phase 2 dosage, form a pharmacokinetics profile, and assess the clinical activity of SRA737. The study met its primary endpoints, paving the way for a further study of the molecule’s effectiveness.
Patients treated with SRA737 combined with low-dose gemcitabine tolerated the drugs well. Furthermore, lower myelotoxicity was observed in the patients compared to those treated solely with gemcitabine or combined with other Chk1 inhibitors.
The data also showed that the objective response rate (ORR) in anogenital cancer was 25%. In contrast, partial tumour responses were seen in other solid tumours, such as cervical cancer, anogenital cancer, rectal cancer, high-grade serous ovarian cancer, and small-cell lung cancer.
Sareum shares are down 64.83% this year, and most shareholders hope they will recover soon.
*This is not investment advice.
Sareum share price.
The Sareum share price rose 4.76% to trade at 90.10p, rising from Friday’s closing price of 86.00p.
